论文部分内容阅读
目的:将大剂量地塞米松对原发性免疫性血小板减少症患者的影响进行探讨,旨在提高原发性免疫性血小板减少症患者的治疗效果。方法:选择我院2014年2月到2017年2月期间收治的原发性免疫性血小板减少症患者作为受试对象,随机选取60例进行本次研究,患者根据治疗方式不同分为两组,每组30例,将两组患者治疗效果进行对比。结果:A组患者症状的缓解效果显著优于B组,差异有统计学意义(P<0.05);B组患者不良反应发生率(16.0%)显著高于A组(4.0%),差异有统计学意义(P<0.05)。结论:对于原发性免疫性血小板减少症患者,建议采用大剂量地塞米松进行冲击治疗,能够显著改善患者症状,且临床应用的安全性高,有临床推广的价值。
OBJECTIVE: To investigate the effects of high-dose dexamethasone on patients with idiopathic thrombocytopenia and to improve the therapeutic effect of patients with idiopathic thrombocytopenia. Methods: A total of 60 patients with idiopathic thrombocytopenia who were admitted to our hospital from February 2014 to February 2017 were randomly selected for this study. The patients were divided into two groups according to the different treatment methods. Each group of 30 cases, the treatment effect of two groups were compared. Results: The relief of symptoms in group A was significantly better than that in group B (P <0.05). The incidence of adverse reactions in group B (16.0%) was significantly higher than that in group A (4.0%) Significance (P <0.05). CONCLUSIONS: For patients with idiopathic thrombocytopenia, high dose dexamethasone is recommended for shock therapy, which can significantly improve the symptoms of patients and provide high safety and clinical value for clinical application.